+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients



Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients



Revista Clinica Espanola 202(10): 543-545



The hepatitis C infection is highly prevalent among HIV-infected patients. As a direct consequence of the increased survival of these patients in the HAART era, liver disease and its long-term complications have became a genuine health problem in these patients. The treatment of chronic HCV hepatitis is associated with several secondary effects, hiperlactacidemiae/lactic acidosis is one of the most dangerous. It appears to be related with the association of ribavirin and ddI, d4T or AZT. These are three cases of hiperlactacidemiae/lactic acidosis collected during the first twelve months of treatment with pegylated interferon and ribavirin in University Hospital of Guadalajara.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047239805

Download citation: RISBibTeXText

PMID: 12361553


Related references

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of Infection 53(1): 36-42, 2006

Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients. Antiviral Therapy 12(4): 459-468, 2007

Safety and efficacy of pegylated interferon alfa 2b plus ribavirin for the treatment of chronic hepatitis c in hiv coinfected patients 48 week results. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1209, 2003

Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients. Enfermedades Infecciosas Y Microbiologia Clinica 24(3): 213-214, 2006

Preventing lactic acidosis in HIV HCV coinfected patients during interferon and ribavirin treatment Development of a real time PCR for mitochondrial DNA copy number in PBMCs. Hepatology 36(4 Part 2): 230A, 2002

Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 53(3): 146-153, 2010

Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients. Expert Review of Anti-Infective Therapy 2(3): 341-342, 2004

Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission. Revista do Instituto de Medicina Tropical de Sao Paulo 48(2): 109-112, 2006

Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment. Gut and Liver 1(1): 87-89, 2007

Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Seminars in Liver Disease 25(1): 33-51, 2005

Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. Journal of Acquired Immune Deficiency Syndromes 45(4): 439-444, 2007

Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. Journal of Antimicrobial ChemoTherapy 67(6): 1449-1452, 2012

Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. Journal of Virology 85(12): 5961-5969, 2011

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis. Intervirology 58(4): 242-249, 2015

Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antiviral Therapy 9(4): 505-509, 2004